Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lonza, a supplier to the pharmaceutical, healthcare and life science industries and Crucell, a biopharmaceutical company, have entered into a co-exclusive manufacturing, sales and distribution agreement related to the Permexcis cell culture medium developed by Crucell for PER.C6 cells.
Subscribe to our email newsletter
Under this agreement, Lonza will manufacture the medium, and in addition will market and sell it on a global basis. Financial details of the agreement were not disclosed.
The Permexcis medium is a chemically defined cell culture medium that does not contain human- or animal-derived components. Permexcis medium was developed for the cultivation of PER.C6 cells and has been designed for use in the large-scale manufacture of biopharmaceutical products including vaccines.
This novel medium has proven, in a comparison study performed by Crucell, to provide higher viral vaccine product yields in PER.C6 based manufacturing processes than some of the current available media for PER.C6 cells on the market.
Ronald Brus, Crucell’s CEO, said: “We are pleased to have entered into this agreement with Lonza. Over 60 companies and organizations have already selected our PER.C6 technology to develop their own products across a wide range of therapeutic areas. We are proud that Lonza will manufacture the Permexcis cell culture medium and in addition will market and sell it globally.”